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Abstract
Background: Mutations of genes affecting surfactant homeostasis, such as SFTPB, SFTPC and ABCA3, lead to diffuse
lung disease in neonates and children. Haploinsufficiency of NKX2.1, the gene encoding the thyroid transcription
factor-1 (TTF-1) - critical for lung, thyroid and central nervous system morphogenesis and function - causes a rare
form of progressive respiratory failure designated brain-lung-thyroid syndrome. Molecular mechanisms involved in
this syndrome are heterogeneous and poorly explored. We report a novel TTF-1 molecular defect causing recurrent
respiratory failure episodes in an infant.
Methods: The subject was an infant with severe neonatal respiratory distress syndrome followed by recurrent
respiratory failure episodes, hypopituitarism and neurological abnormalities. Lung histology and ultrastructure were
assessed by surgical biopsy. Surfactant-related genes were studied by direct genomic DNA sequencing and array
chromatine genomic hybridization (aCGH). Surfactant protein expression in lung tissue was analyzed by confocal
immunofluorescence microscopy. For kinetics studies, surfactant protein B and disaturated phosphatidylcholine
(DSPC) were isolated from serial tracheal aspirates after intravenous administration of stable isotope-labeled 2H2O
and 13C-leucine; fractional synthetic rate was derived from gas chromatography/mass spectrometry 2H and 13C
enrichment curves. Six intubated infants with no primary lung disease were used as controls.
Results: Lung biopsy showed desquamative interstitial pneumonitis and lamellar body abnormalities suggestive of
genetic surfactant deficiency. Genetic studies identified a heterozygous ABCA3 mutation, L941P, previously
unreported. No SFTPB, SFTPC or NKX2.1 mutations or deletions were found. However, immunofluorescence studies
showed TTF-1 prevalently expressed in type II cell cytoplasm instead of nucleus, indicating defective nuclear
targeting. This pattern has not been reported in human and was not found in two healthy controls and in five
ABCA3 mutation carriers. Kinetic studies demonstrated a marked reduction of SP-B synthesis (43.2 vs. 76.5 ± 24.8%/
day); conversely, DSPC synthesis was higher (12.4 vs. 6.3 ± 0.5%/day) compared to controls, although there was a
marked reduction of DSPC content in tracheal aspirates (29.8 vs. 56.1 ± 12.4% of total phospholipid content).
Conclusion: Defective TTF-1 signaling may result in profound surfactant homeostasis disruption and neonatal/
pediatric diffuse lung disease. Heterozygous ABCA3 missense mutations may act as disease modifiers in other
genetic surfactant defects.
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Introduction
Genetic disorders of surfactant homeostasis are a rare
cause of respiratory failure in newborns and infants [1].
Bi-allelic loss-of-function mutations of SFTPB, the gene
encoding surfactant protein-B (SP-B) [2,3] and ABCA3,
which encodes ATP-binding cassette transporter A3
(ABCA3) typically present as lethal respiratory distress
syndrome in neonates [4-6]. Bi-allelic ABCA3 mutations
[7,8] and mono-allelic mutations of SFTPC, the gene
encoding surfactant protein-C (SP-C), [9-11] may also
cause later-onset, progressive interstitial lung disease
spanning from infancy to adulthood. Thyroid transcrip-
tion factor-1 (TTF-1), also known as NK2 homeobox-1
(NKX2.1) or thyroid-specific enhancer-binding protein
(T/EBP), plays a role in embryogenesis and morphogen-
esis of the lung, brain and thyroid gland [12-14], and
regulates the expression of a series of genes implied in
surfactant synthesis [15]. TTF-1 haploinsufficiency sec-
ondary to deletions or mono-allelic mutations of the
NKX2.1 gene has been recognized as a rare cause of
neonatal or infantile respiratory failure, often associated
with congenital hypothyroidism and/or benign heredi-
tary chorea [16-20], referred to as “brain-lung-thyroid
syndrome”. These genetic disorders are associated with
various disruptions of surfactant synthesis and composi-
tion [17,21]. Recently, a double stable isotope labeling
approach has been described for in vivo endogenous
surfactant kinetics assessment [22]. We report a patient
with severe neonatal respiratory distress syndrome
(RDS), recurrent respiratory failure episodes in infancy,
pituitary anatomical and functional anomalies, and mild
neurological symptoms suggestive of brain-lung-thyroid
syndrome, in which extensive surfactant-related gene
sequencing failed to identify identified NKX2.1 muta-
tions and showed only a previously unreported ABCA3
missense mutation carried in heterozygosis.
Materials and methods
Patient’s clinical history
The infant was a first male child born at 40 weeks of
gestation by vaginal delivery, with a one- and five-minute
Apgar score of 8 and 9 and normal birth weight. The
infant was a first child, and the parents, of east European
descent, were non-consanguineous and reportedly
healthy. Soon after birth he presented with respiratory
distress and hypoxemia, requiring intubation and
mechanical ventilation. Since hypoxemia progressed, the
infant required three doses of poractant alpha, high-fre-
quency oscillatory ventilation, plus inhaled nitric oxide
(iNO) and milrinone. Extubation at seventeen days failed,
and mechanical ventilation and iNO were resumed for
additional five days. Dexamethasone was added for four-
teen days, as well as sildenafil, and the infant was dis-
charged at thirteen weeks in room air. He was readmitted
twice in pediatric intensive care unit for respiratory fail-
ure and pulmonary hypertension relapse in the course of
viral respiratory infections, at the age of four and seven
months, and was treated with poractant alpha, dexa-
methasone, iNO and ventilation for four and nine days
respectively. At seven months, a surgical lung biopsy was
performed after obtaining parental consent. At one year,
failure to thrive, delayed developmental milestones and
moderate axial hypotonia became evident. Free thyroxin
(FT4) level was 4.5 pg/mL (8.0-19), free triiodothyronine
(FT3) was 2.9 pg/mL (1.8-19.0) and thyroid-stimulating
hormone (TSH) was 1.25 mUI/L (0.4-4.0). Growth Hor-
mone (GH) levels at baseline and after two separate argi-
nine stimulation tests were <0.5 ng/mL (normal: >10).
Cortisol at baseline and after adrenocorticotropic hor-
mone (ACTH) stimulation test was normal. Baseline
ACTH was normal. Brain MRI showed an ectopic and
hypoplastic pituitary gland, partial optical nerve atrophy,
and bilateral occipital white matter injury. Thyroid gland
ultrasonography was unremarkable.
Surfactant-related gene sequence analysis
SFTPB, SFTPC and ABCA3 genes were analyzed by
direct sequencing of PCR-amplified products from geno-
mic DNA as published [2,4,23]. Two sets of specific pri-
mers were used for amplification of the whole NKX2.1
coding and non-coding regions, the sequences of which
are available on request. Results were compared to pub-
lished reference sequences [ENSG00000168878], [ENSG
00000168484], [ENSG00000167972] and [ENSG
00000136352] respectively. Genomic rearrangements
were studied by array chromatin genomic hybridization
(aCGH) using a 60 K microarray (Agilent hg19, Agilent
Technologies, Santa Clara, CA, USA). Genetic studies
were conducted after obtaining parental informed con-
sent. These studies were performed in compliance with
the Bambino Gesù Children’s Hospital Ethics Commit-
tee guidelines.
Microscopic studies
Sections of formalin-fixed lung tissue were analysed with
hematoxylin-eosin (HE), Masson Trichrome (MT), Peri-
odic Acid Shiff (PAS) and Van Gieson (VG) stainings.
For immunofluorescence studies, serial lung cryosections
were fixed with 4% paraformaldehyde in phosphate buf-
fered saline labeled with monoclonal antibodies against
SP-B (Labvision, Fremont, CA), TTF-1 and ABCA3
(clone 13-H2-57, Seven Hills Bioreagents, Cincinnati,
OH) or polyclonal antibodies against proSP-B and pro
SP-C, transforming growth factor-b1 (TGF-b1) and
SMAD3 (Chemicon Inc., Temecula, CA). The immunor-
eaction was revealed with goat anti-mouse or anti-rabbit
Alexa Fluor 488-conjugated immunoglobulins (Molecular
Probes, Eugene, OR), or with a goat anti-rabbit Alexa
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Fluor 555-conjugated antibody (in TTF-1/proSP-C dou-
ble immunostaining). Nuclear staining was performed
with Hoechst 33342 (Molecular Probes). Image acquisi-
tion were performed using an Olympus Fluoview FV1000
confocal microscope equipped with FV10-ASW version
1.6 software, and processed with Adobe Photoshop soft-
ware version 9.0. Ultrathin 1 μ sections obtained from
Karnowsky-osmium tetroxide post-fixed and epon-
embedded samples contrasted with lead citrate and ura-
nyl acetate were analyzed with a Zeiss 902 transmission
electron microscope. For quantitative lamellar body ana-
lysis, mean count per cell and diameter measurement
were derived from10 random sections at 3000 × magnifi-
cation picturing single type II cell cross-section. Normal
human lung tissue obtained from a lobectomy specimen
in a 3-month old infant with congenital cystic adenoid
malformation and lung biopsies from five infants with
ABCA3 mutations (one homozygous frameshift mutation
carrier, one double heterozygous missense mutations car-
rier and three heterozygous missense mutation carriers)
were used as controls after parental consent.
Surfactant composition and kinetics
After parental informed consent was obtained, the patient
received a 24 h IV infusion of 1-13C leucine stable isotope,
2 mg/kg/h and a 48 h 2H2O stable isotope administration,
given as 2 mL/Kg bolus followed by 0.125% of total fluid
intake, according to a previously published research proto-
col approved by the conducting institution review board
[24,25]. Serial blood, urine and tracheal aspirate (TA) sam-
ples were collected for a 48 h period. TA supernatant was
separated by centrifugation. Disaturated phosphatidylcho-
line (DSPC) - the main phospholipid (PL) component in
human surfactant- and SP-B were isolated by solid phase
extraction and thin layer chromatography. DSPC was
quantified by gas-chromatography (GC) and DSPC and
SP-B kinetics measured by GC-isotope ratio-mass spectro-
metry (IRMS) and GC-mass spectrometry (GC-MS)
respectively. 13C Leucine enrichment at plateau in plasma
aminoacids was determined by GC-MS. Deuterium
enrichment in urine was determined with a thermal con-
version/elemental analyzer coupled with an IRMS to
determine 2H2O plateau enrichment. Fractional synthetic
rate was derived from the linear increase of the SP-B 13C
leucine and of the DSPC 2H-palmitate respectively, as
published. Six infants with gestational age >37 weeks, intu-
bated and ventilated for conditions unrelated to parenchy-
mal lung disease, who underwent the same protocol after
parental consent, were used as controls.
Results
Morphology
Lung microscopy revealed diffuse interstitial thickening
with thin collagen fiber deposits on MT- and VG-stained
sections, and with predominantly lymphomonocytic
(CD45 positive) cell infiltrates plus some neutrophils and
eosinophils, alveolar type II (proSP-B positive) cell hyper-
plasia and abundant clusters of intra-alveolar macrophages
(CD68-positive) with a foamy, PAS-positive cytoplasm, a
pattern corresponding to desquamative interstitial pneu-
monitis (DIP). Alveolar spaces were normal-sized, and,
within the limits of the sample, bronchiolar architecture
was unremarkable. Only minor intra-alveolar amorphous
material was seen (PAS), which excluded alveolar protei-
nosis. Arterioles did not show significant signs of remodel-
ing, and the pulmonary capillary bed was quantitatively
and morphologically well represented (CD31) (figure 1).
On transmission electron microscopy, lamellar bodies
count per cell were similar to control (15.3 ± 3.1 vs. 14.4 ±
4.0) but their diameter was smaller (618 ± 98 vs. 852 ±
135 nm), with few electron-dense concentric membranes
and a denser central core similar as those found in
ABCA3 deficiency [26,27] (figure 2).
Molecular genetics
SFTPB sequencing revealed the presence of the homozy-
gous c2052 C>A and the heterozygous c2619 T>C poly-
morphisms. SFTPC sequencing showed the presence of
the homozygous c2772 A>G and c2643 C>G poly-
morphisms. ABCA3 sequencing showed a mono-allelic
variation, c3381 T>C, leading to the aminoacidic
sequence change L941P, not previously reported, which
was carried by the father and was not present in 100
control alleles, hence to be considered a novel heterozy-
gous missense mutation. On NKX2.1 sequencing, four
common variants were present: rs76977831, rs77021012,
rs117543880, rs117216249. In addition we found a inser-
tion variant in the 3’UTR-coding region, 1636_1637 ins
AC, but it was found to be present in the proband’s
mother and in 3 out of 60 alleles from unaffected
infants, one being homozygous carrier for this variant,
which therefore doesn’t appear to be disease-causing.
The aCGH analysis did not reveal copy number varia-
tions in the NKX2.1, ABCA3, SFTP-B and SFTP-C loci.
Surfactant-related protein expression
ABCA3 expression was moderately decreased, while
proSP-B, mature SP-B and proSP-C expression were
similar in the patient compared to control (figure 3). In
the control, as described in the literature [28], TTF-1
was almost exclusively expressed in the nuclei of alveo-
lar type II cells, as shown by co-expression of pro-SP-B
(not shown), whereas in the patient, it appeared mostly
confined to the cytoplasm and barely detectable in the
nucleus (figure 4). This pattern was not found in the
five ABCA3 mutation controls (not shown). TGF-b1 and
SMAD3 expression resulted similar to controls (not
shown).
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Figure 1 Lung tissue morphology. a: normal control (healthy lung tissue obtained from lobectomy in a 1-month old infant with congenital
cystic adenoid malformation), optical microscopy, 20 ×; b-i: patient’s lung tissue obtained by open-chest biopsy at 7 months. a: Normal lung
tissue, HE, 20 ×; b: low-power microscopy shows interstitial thickening, alveolar type II cell hyperplasia and intra-alveolar amorphous material (HE
20 ×); c: sparse intracellular and intra-alveolar proteinaceous material accumulation (PAS, 20 ×); d: Diffuse interstitial fibrosis (MT, 20 ×); e: Small
collagen fiber deposition in the interstitium (VGFE, 20 ×); Regular density and distribution of pulmonary capillary vessels (factor VIII, 20 ×); g:
Higher magnification shows leukocyte intra-alveolar accumulation and interstitial infiltration (CD45, 40 ×); h: intra-alveolar cells mostly correspond
to macrophages (CD68, 400 ×); i: alveolar epithelial lining consists of hyperplastic type-II cells (proSP-B, 40 ×).
Figure 2 Alveolar type II cell ultrastructure. Transmission electron microscopy of lung tissue. A. normal lung tissue of a 5 month-old infant
obtained from lobectomy for congenital cystic adenoid malformation showing a type II cell with numerous lamellar bodies filled with concentric
pseudomyelin membranes, magnification 3000 ×. B. Detail of one lamellar body, 8000 ×. C. lung tissue form the patient’s biopsy, showing a type II
cell with smaller, denser lamellar bodies. D. Detail of one lamellar body with poorly structured content, Magnification bar: 1 μm.
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Phospholipid and SP-B composition and metabolism
The surfactant kinetic study was conducted at the age of
8 month, while the patient was admitted the pediatric
intensive care for a respiratory failure relapse. There was
a marked (~50%) reduction of DSPC (29.8 vs. 56.1 ±
12.4% PL) in the patient’s TA compared to controls
values from our laboratory (mean ± standard deviation).
DSPC fractional synthesis rate was significantly
increased in the patient compared to controls (12.4 vs.
6.3 ± 0.5%/day), while SP-B synthesis rate was markedly
reduced (43.2 vs. 76.5 ± 24.8%/day) (figure 3).
Discussion
TTF-1 is a transcription factor accepted as a master reg-
ulator of foregut and forebrain structures development.
Complete TTF-1 absence in the NKX2.1 null mouse
leads to non-viable progeny with defective lung organo-
genesis and bronchial branching, absent thyroid gland,
forebrain anomalies and absent pituitary [12,13]. In the
lung, TTF-1 is expressed in the alveolar epithelium and
is required for type II cell differentiation and surfactant
protein expression. Pulmonary pathology in human sub-
jects with TTF-1 haploinsufficiency is characterized by
mixed features of lung development impairment
(reduced airway generations and radial alveolar count,
distal bronchiolar cysts) and surfactant homeostasis dis-
ruption (focal alveolar septal fibrosis, alveolar type II cell
hypertrophy and clusters of alveolar macrophages)
[19,29]. Cytoplasm-restricted TTF-1 expression in type-
II cells has not been, to our knowledge, observed in sub-
jects with diffuse lung disease. In our case, optical and
ultrastructural morphology are more indicative of a sur-
factant defect, while no developmental abnormalities are
observable [30]. Complete TTF-1 cytoplasmic restriction
would be expected to abolish homeodomain nuclear
transcription, which is not compatible in this case. Some
degree of residual TTF-1 nuclear targeting may explain
the observed phenotype. A similar pattern has been
reported in an in vitro mutagenesis study reproducing a
human NKX2.1 mutation [31]; hence it could represent
an alternative molecular mechanism in certain cases of
TTF-1 haploinsufficiency. TTF-1 cytoplasmic trapping
was also observed in vitro in human lung cultures
exposed to phorbol ester -a nuclear translocation-block-
ing compound [32]- or to TGF-b1 [33]; in these experi-
ments, cytoplasmic trapping of TTF-1 -a known
inductor of SFTPB and SFTPC genes-resulted in SFTPB
down-regulation [34]. For this reason we studied TGF-
b1 and SMAD3 expression, but it resulted similar to
controls. Moreover, a more pervasive defect of the
nuclear translocation machinery of the cell appears very
unlikely, since it would affect many nuclear proteins and
would probably not be viable. Our patient had a 50%
reduction of SP-B synthesis rate, a finding consistent
with the fact that SP-B and SP-C content is altered in
tracheal aspirates of patients with TTF-1 deficiency
[16,17]. These data suggest that decreased SP-B synth-
esis due to defective TTF-1 nuclear translocation con-
tributed to the respiratory phenotype.
We also showed a marked reduction of DSPC content
in the alveolar fluid, despite an increased fractional
Figure 3 Surfactant-related protein expression. Confocal
microscopy of lung biopsies from control (a, c, e, g) and patient (b,
d, f, h), immunolabeled with antibodies against ABCA3 (a-b), pro SP-
B (c-d), SP-B (e-f), pro SP-C (g-h) antibodies. ABCA3 labeling showed
a faint and homogeneous reduction in the type II cell population in
patient compared to control, whereas pro SP-B, SP-B and pro SP-C
protein expression was similar. Magnification bar: 20 μm.
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synthesis rate. Such a finding has been described in TA
of patients with ABCA3 deficiency [35] and in ABCA3-
deficient mice [36]. ABCA3, which encodes a transmem-
brane phospholipid transporter critical for intracellular
surfactant assembly and packaging [36], is also a target
gene for TTF-1 [37]. Indeed, ABCA3 expression
appeared decreased in our patient. Moreover, he carried
a novel ABCA3 missense mutation in heterozygosis.
Since this variation has not been previously described,
mutagenesis studies would be necessary to fully assess
its relevance; however, its location in the 7th transmem-
brane domain coding sequence suggests it potentially
affects protein function [38]. Mono-allelic ABCA3 mis-
sense mutations have been reported as modifiers of
other genetic surfactant defects [39,40] and may increase
RDS severity in susceptible individuals [41]. Overall we
can speculate that partial ABCA3 insufficiency due to
the combined effects of TTF-1 cytoplasmic trapping and
the missense ABCA3 mutation further contributed to
respiratory phenotype, causing a latent surfactant home-
ostasis disorder with exacerbation under stress circum-
stances such as viral infection.
Although the clinical phenotype and immunolocaliza-
tion studies strongly suggest a TTF-1 genetic defect
leading to partially defective nuclear targeting, we were
not able to demonstrate any mutation or deletion affect-
ing coding and non-coding regions of the NKX2.1 gene.
We cannot formally exclude post-transcriptional anoma-
lies or variations not accessible by the techniques
applied in this case, and even if our data do not support
a role of TGFb in TTF-1 sequestration, we cannot
exclude anomalies in other genes interfering with TTF-1
nuclear translocation. Since we were unable to show
TTF-1 trapping in other homozygous or heterozygous
ABCA3 mutation carriers in our hands, and since no
data in the literature suggest that ABCA3 affects
NKX2.1 expression, it is unlikely that the TTF-1 target-
ing defect is secondary to the ABCA3 mutation.
TTF-1 plays an essential role in central nervous sys-
tem morphogenesis. To our knowledge, brain imaging
and histology studies in subjects affected by TTF-1 hap-
loinsufficiency are usually negative or nonspecific
[19,20]. However, heterozygous interstitial chromosome
14q deletions encompassing NKX2.1 may be associated
with pituitary hypoplasia and ocular anomalies [42-44],
and in animal studies TTF-1 is critical for forebrain and
pituitary embryogenesis [12]. Hence, in our case pitui-
tary malformation is presumably caused by TTF-1 sig-
naling disruption, leading to central hypopituitarism and
GH deficiency. This pattern differs from the peripheral
Figure 4 TTF-1 expression. Lung tissue immunolabeled with anti-TTF-1 antibody (green) and nuclear labelling (Hoechst 33342, blue), confocal
microscopy. a-b: TTF-1 expression in normal lung is confined to nuclear districts. c-d: TTF-1 protein distribution in patient’s lung is markedly
decreased in alveolar type II cell nuclei (c) and predominantly confined in their cytoplasm. Magnification bar: 20 μm.
Peca et al. Respiratory Research 2011, 12:115
http://respiratory-research.com/content/12/1/115
Page 6 of 8
hypothyroidism typically associated with TTF-1
haploinsufficiency.
In summary we report a complex surfactant homeos-
tasis disorder caused by a TTF-1 defect of unknown ori-
gin, not previously described, combined to a novel
heterozygous ABCA3 mutation in a patient with brain-
lung-thyroid syndrome. Although this compound
genetic disorder may remain unique to this kindred, it
highlights the importance of conducting extensive mor-
phological, molecular and genetic studies in patients
with unexplained diffuse lung disease in order to estab-
lish solid genotype-phenotype correlations and identify
new genetic defects in this highly heterogeneous and
under-recognized group of diseases.
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